2022
Aqilion reinforces its position as a biotech company.
The drug candidate AQ312, a new treatment of chronic inflammatory bowel diseases (IBD), strengthens and complements the pipeline.
In August, Aqilion started a Phase 1 safety study with the drug candidate AQ280 (Regulus program) in healthy volunteers.